Tovetumab
Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.[2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | PDGFRA |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6400H9906N1726O2002S54 |
| Molar mass | 144792.97 g·mol−1 |
This drug was developed by MedImmune, LLC.
References
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF | |||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| |||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.